The open-label extension RIDE and RISE phase III studies of ranibizumab (Lucentis, Genentech) indicated that the beneficial results of the drug for treating diabetic macular edema were maintained over the long-term with less than monthly follow-up or injection treatment.
Phiadelphia—The RIDE and RISE phase III long-term extension studies of ranibizumab (Lucentis, Genentech) indicated that the beneficial results of the drug for treating diabetic macular edema (DME) were maintained over the long-term, according to Allen Ho, MD, FACS.
About 25% of the study patients did not need retreatment, and in most patients requiring further treatment, the drug could be administered on less than a monthly basis to maintain the visual acuity (VA) gains.
The results of the core RIDE and RISE trials demonstrated the efficacy of ranibizumab for treating DME with the 0.3-mg and 0.5-mg doses, Said Dr. Ho, director of retina research at Wills Eye Hospital, Philadelphia. Patients with DME who completed masked, monthly treatment with ranibizumab at month 36 of the core study then could enter the open-label extension trials. The investigators sought to answer the following clinically relevant questions:
- Can patients maintain visual gains achieved with initial monthly therapy when they transition to as-needed therapy?
- What frequency of retreatment is sufficient to maintain the vision gains?